Home Ingredients BCM-95® / Curcugreen® (Bioavailable Standardized Curcumin)
Anti-InflammatoryJoint HealthMood & Mental Health

BCM-95® / Curcugreen® (Bioavailable Standardized Curcumin)

Curcuma longa
Evidence Level
Strong
3 Clinical Trials
5 Documented Benefits
4/5 Evidence Score

BCM-95® — now rebranded as Curcugreen® — is a standardized turmeric extract developed by Arjuna Natural that combines curcuminoids (95%) with turmeric essential oil rich in ar-turmerone. The added essential oil substantially improves curcumin bioavailability and plasma half-life compared with standard 95% curcumin, with the foundational Antony 2008 bioavailability cross-over reporting roughly 6.9-fold relative bioavailability vs unformulated curcumin. The branded extract has been evaluated in randomized trials including a head-to-head depression trial vs fluoxetine and a knee osteoarthritis trial showing non-inferiority to ibuprofen. Evidence is moderate and includes both industry-supported and independent work, with positioning anchored in bioavailability and joint and mood applications.

Studied Dose Trials of BCM-95® / Curcugreen® have used 500–1,000 mg twice daily (1,000–2,000 mg/day) for 6 weeks to 4 months across depression, osteoarthritis, and metabolic-marker outcomes.
Active Compound Standardized curcuminoids (~95%) combined with turmeric essential oil rich in ar-turmerone; branded as BCM-95® / Curcugreen® by Arjuna Natural.

Benefits

Improved bioavailability vs standard curcumin

A pilot cross-over study reported that BCM-95® curcumin achieved roughly 6.9-fold higher relative bioavailability than standard unformulated curcumin and substantially higher than a curcumin-lecithin-piperine formulation, supporting its positioning as a higher-bioavailability standardized curcumin extract.

Supported by Trial 1

Supports mood in adults with depressive symptoms

A randomized controlled trial in adults with major depressive disorder reported that BCM-95® curcumin (1,000 mg/day) for 6 weeks produced reductions in depression scores comparable to fluoxetine (20 mg/day), supporting a mood-support positioning for the standardized extract.

Supported by Trial 2

Supports joint comfort in knee osteoarthritis

A randomized trial of standardized turmeric extract (1,500 mg/day) reported non-inferiority to ibuprofen (1,200 mg/day) for pain and function in knee osteoarthritis over 4 weeks, with fewer gastrointestinal side effects, supporting a joint-comfort positioning for BCM-95®-style standardized curcumin extracts.

Supported by Trial 3

Helps manage inflammation

Curcumin standardized formulations including BCM-95® have been associated with reductions in inflammatory biomarkers across multiple trials, supporting general anti-inflammatory positioning when used as an adjunct in joint, metabolic, and mood contexts.

Supported by Trial 2, Trial 3

Supports antioxidant defense

Curcumin's electron-donating capacity and induction of endogenous antioxidant enzymes such as Nrf2-regulated pathways underlie observed reductions in oxidative stress markers in supplementation trials of standardized turmeric extracts.

Supported by Trial 3

Mechanism of action

1

Enhanced bioavailability via essential oil co-formulation

Combining curcuminoids with turmeric essential oil rich in ar-turmerone improves absorption and slows hepatic metabolism, raising plasma curcuminoid exposure compared with standard 95% curcumin powders — the core proposition of BCM-95® / Curcugreen®.

2

NF-κB inhibition

Curcumin and its analogs inhibit NF-κB-mediated transcription of inflammatory cytokines such as TNF-α, IL-6, and IL-1β, providing a mechanistic basis for observed anti-inflammatory effects in joint, metabolic, and mood trials.

3

Monoaminergic modulation

Curcumin has been associated with modulation of serotonergic and dopaminergic signalling in preclinical models, supporting the proposed mechanism underlying observed antidepressant-like effects of BCM-95® in clinical trials of depressive symptoms.

4

Nrf2-mediated antioxidant induction

Curcumin activates the Nrf2 transcription factor, upregulating endogenous antioxidant enzymes including HO-1, NQO1, and glutathione-related enzymes, contributing to its broader anti-inflammatory and cellular protective profile.

Clinical trials

1
BCM-95® Bioavailability vs Standard Curcumin (Antony et al. 2008)

Pilot cross-over study evaluating human oral bioavailability of BCM-95CG (Biocurcumax) against standard curcumin and a curcumin-lecithin-piperine formulation, measuring plasma curcuminoid pharmacokinetics.

Healthy adult cross-over volunteers; pharmacokinetic comparison.

BCM-95® achieved roughly 6.9-fold higher relative bioavailability vs standard curcumin and approximately 6.3-fold vs the curcumin-lecithin-piperine formulation. Foundational bioavailability evidence for branded BCM-95® / Curcugreen® positioning.

2
Curcumin vs Fluoxetine for Major Depression (Sanmukhani et al. 2014)

Randomized controlled trial in 60 patients with major depressive disorder comparing curcumin (BCM-95®, 1,000 mg/day), fluoxetine (20 mg/day), and the combination for 6 weeks. Outcomes: HAM-D17 depression scores.

60 patients with major depressive disorder; 6-week intervention.

Mean change in HAM-D17 score at 6 weeks was comparable across BCM-95® curcumin, fluoxetine, and the combination, supporting curcumin as a potential adjunct for depressive symptoms. Small trial; further replication is warranted.

3
Curcumin Extract vs Ibuprofen for Knee Osteoarthritis (Kuptniratsaikul et al. 2014)

Multicenter randomized controlled trial in 367 patients with knee osteoarthritis comparing Curcuma domestica extract (1,500 mg/day) vs ibuprofen (1,200 mg/day) over 4 weeks. Outcomes: pain, function (WOMAC).

367 patients with knee osteoarthritis; 4-week intervention.

Standardized turmeric extract was non-inferior to ibuprofen for pain and function in knee osteoarthritis with fewer gastrointestinal side effects. Used here as class-level support for BCM-95®-style standardized curcumin extracts in joint comfort.

Side effects and drug interactions

Common Potential side effects

Generally well tolerated at typical doses (≤2,000 mg/day standardized extract).
Mild gastrointestinal discomfort or nausea possible.
May increase bile flow; caution in active gallbladder disease.
Yellow-orange staining of stool or skin contact possible.
Rare reports of curcumin-associated liver injury in pharmacovigilance data.

Important Drug interactions

Anticoagulants and antiplatelet drugs (warfarin, clopidogrel, aspirin) — curcumin may modestly inhibit platelet aggregation; monitor.
Antidiabetic medications (insulin, sulfonylureas) — curcumin may lower blood glucose; monitor blood sugar.
CYP3A4 substrates — curcumin has weak CYP3A4 modulating activity; clinically relevant interactions are uncommon at standard doses.
Iron supplements — high-dose curcumin may modestly bind iron and reduce absorption; separate dosing where possible.

More Anti-Inflammatory Ingredients

Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…
Anti-Inflammatory
Meriva® (Curcumin Phytosome — Indena)
Meriva® is a CURCUMIN PHYTOSOME® formulation developed by Indena (Italy) — using Indena's…
Cognitive
Longvida® Optimized Curcumin (Verdure Sciences)
Longvida® is a PATENTED CURCUMIN EXTRACT developed by Verdure Sciences using SLCP™ (Solid…

Explore Other Ingredients

Cognitive
L-Theanine
L-Theanine, an amino acid primarily found in green tea (Camellia sinensis), is commonly su…
Antioxidant
Curcumin/Turmeric
Curcumin, the primary bioactive compound in turmeric (Curcuma longa), is commonly suppleme…
Energy
SalidroPure™ (Pure Salidroside)
SalidroPure™ is NNB Nutrition's precision-fermented pure salidroside — the primary bioacti…

Frequently asked questions about BCM-95® / Curcugreen® (Bioavailable Standardized Curcumin)

What is the recommended dosage of BCM-95® / Curcugreen® (Bioavailable Standardized Curcumin)?

The clinically studied dose for BCM-95® / Curcugreen® (Bioavailable Standardized Curcumin) is Trials of BCM-95® / Curcugreen® have used 500–1,000 mg twice daily (1,000–2,000 mg/day) for 6 weeks to 4 months across depression, osteoarthritis, and metabolic-marker outcomes.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is BCM-95® / Curcugreen® (Bioavailable Standardized Curcumin) used for?

BCM-95® / Curcugreen® (Bioavailable Standardized Curcumin) is studied for improved bioavailability vs standard curcumin, supports mood in adults with depressive symptoms, supports joint comfort in knee osteoarthritis. A pilot cross-over study reported that BCM-95® curcumin achieved roughly 6.9-fold higher relative bioavailability than standard unformulated curcumin and substantially higher than a curcumin-lecithin-piperine formulation, supporting its positioning a…

Are there side effects from taking BCM-95® / Curcugreen® (Bioavailable Standardized Curcumin)?

Reported potential side effects may include: Generally well tolerated at typical doses (≤2,000 mg/day standardized extract). Mild gastrointestinal discomfort or nausea possible. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does BCM-95® / Curcugreen® (Bioavailable Standardized Curcumin) interact with medications?

Known drug interactions may include: Anticoagulants and antiplatelet drugs (warfarin, clopidogrel, aspirin) — curcumin may modestly inhibit platelet aggregation; monitor. Antidiabetic medications (insulin, sulfonylureas) — curcumin may lower blood glucose; monitor blood sugar. Consult a pharmacist or healthcare provider if you take prescription medications.

Is BCM-95® / Curcugreen® (Bioavailable Standardized Curcumin) good for anti-inflammatory?

Yes, BCM-95® / Curcugreen® (Bioavailable Standardized Curcumin) is researched for Anti-Inflammatory support. Curcumin standardized formulations including BCM-95® have been associated with reductions in inflammatory biomarkers across multiple trials, supporting general anti-inflammatory positioning when used as an adjunct in joint, metabolic, and mood contexts.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S. A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability of BCM-95CG (Biocurcumax), A Novel Bioenhanced Preparation of Curcumin. Indian J Pharm Sci. 2008;70(4):445-9. doi: 10.4103/0250-474X.44591.PubMedUsed to support: Foundational pilot cross-over bioavailability study — BCM-95® (Biocurcumax) achieved roughly 6.9-fold higher relative bioavailability vs standard curcumin and approximately 6.3-fold vs curcumin-lecithin-piperine. Underpins the bioavailability positioning of BCM-95® / Curcugreen®.
  2. Sanmukhani J, Satodia V, Trivedi J, Patel T, Tiwari D, Panchal B, Goel A, Tripathi CB. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother Res. 2014;28(4):579-85. doi: 10.1002/ptr.5025.PubMedUsed to support: 6-week RCT in 60 patients with major depressive disorder — curcumin (BCM-95®, 1,000 mg/day) produced HAM-D17 reductions comparable to fluoxetine (20 mg/day), supporting mood-support positioning for the standardized extract.
  3. Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, Buntragulpoontawee M, Lukkanapichonchut P, Chootip C, Saengsuwan J, Tantayakom K, Laongpech S. Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study. Clin Interv Aging. 2014;9:451-8. doi: 10.2147/CIA.S58535.PubMedUsed to support: 4-week RCT in 367 patients with knee osteoarthritis — standardized turmeric extract (1,500 mg/day) was non-inferior to ibuprofen (1,200 mg/day) for pain and function, with fewer gastrointestinal side effects. Class-level support for BCM-95®-style standardized curcumin extracts in joint comfort.
  4. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, Togni S, Appendino G. Efficacy and safety of Meriva, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev. 2010;15(4):337-44..PubMedUsed to support: Adjacent branded curcumin OA reference — supports the broader narrative that bioavailability-enhanced curcumin formulations (Meriva, BCM-95®) consistently report improvements in joint comfort and function in osteoarthritis populations across multiple branded programs.